

Zydus launches trivalent flu vaccine VaxiFlu in India

Unlike the traditional quadrivalent vaccines which targets four strains, Zydus vaccine is a trivalent inactivated therapy which ensures protection against three seasonal influenza virus strains outlined in the WHO's annual surveillance and recommendations.



Ahmedabad: Indian pharma major Zydus Lifesciences has announced the launch of its trivalent influenza vaccine 'VaxiFlu' in India

VaxiFlu is a trivalent inactivated vaccine which

ensures protection against three seasonal influenza virus strains — two influenza A subtypes (H1N1 and H3N2) and one influenza B lineage— which are also outlined in the WHO's annual surveillance and recommendations.

Earlier flu vaccines were based on a quadrivalent regime which targets four strain, however under their recent guidance regulatory bodies have recommended to remove the fourth strain, as it is no longer active.

“The global pattern of influenza virus circulation since 2020, the influenza B Yamagata virus has not been reported.... so there is no point vaccinating against a virus which is no longer in circulation for the past 5 years, noted Dr. Parvaiz Koul, - FRCP, Pulmonary Medicine, Royal College of Physicians, London.

In India, the Centre for Disease Control (NCDC), under Government of India has also recommended the use of Trivalent Influenza vaccine in the country.

VaxiFlu is administered usually before the cold season when the flu virus becomes more active and highly recommend for high risk group patients including ones with chronic health problems such as diabetes, heart failure, kidney failure, or chronic obstructive pulmonary disease (COPD).

“We believe in aligning with global guidelines and enabling timely access to vaccines, and believe that this will significantly reduce vaccine preventable diseases and related complications in high-risk groups.” said Dr. Sharvil Patel, MD, Zydus Lifesciences.

News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/zydus-introduces-innovative-trivalent-influenza-vaccine-vaxiflu-in-india/123653047>